Data / Form D filings / Memento Medicines, Inc.
Memento Medicines, Inc.: Form D filing
Memento Medicines, Inc., a biotechnology company in Boston, MA, filed a Form D with the SEC in 2026. The latest, on June 16, 2026, reports $38 million sold of a $93 million offering to 7 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 200 BERKELEY ST. 18th Floor, Boston, MA, 02116
- Phone
- (518) 313-0994
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2025
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 2139514
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | New notice | $93,000,383 | $38,000,159 | $55,000,224 | 7 | Jun 3, 2026 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Naveen Manu Daryani | Executive Officer, Director, Promoter | |
| William Daley Bonificio | Executive Officer, Promoter | |
| Stephen Basil Thomas | Executive Officer, Promoter | |
| Zach Scheiner | Director | |
| Dmitrij Hristodorov | Director | |
| Megan Krench | Director | |
| Vishal Kapoor | Director |
Other biotechnology companies in Massachusetts that filed recently
- Tru Singular Health, Inc. $1 million · Oct 30, 2026
- 511 Therapeutics, Inc. $500,000 · Oct 30, 2026
- Elucid Bioimaging Inc. $56.2 million · Oct 27, 2026
- OrthoIQ, Inc. $1.1 million · Oct 23, 2026
- LeanBio Therapeutics, Inc. offering · Oct 22, 2026
- Quiver Holdings Inc. $3 million · Oct 21, 2026
Every Form D from the week of Jun 15, 2026 · All recent filings in Massachusetts · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Memento Medicines, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.